Vice President of Market Research at Industry Standard Research Kate Hammeke reviews the challenges biopharma organizations face when engaging CMOs for sterile injectable drug products.
“The explanations provided by respondents who identified a lack of available capacity for small volumes suggest that, while an absence of available capacity isn’t the biggest problem for all respondents, it is a problem that could potentially impact any outsourcer of sterile injectables, which is why it’s ripe for further exploration here.”
Read more at Bioprocess Online, and be sure to check out our Biologic Drug Product and Small Molecule Drug Product Contract Manufacturer Quality Benchmarking reports to learn more about the data these insights were sourced from.
